QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lake-street-initiates-coverage-on-genelux-with-buy-rating-announces-price-target-of-16

Lake Street analyst Chad Messer initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Price Target of ...

 genelux-q2-eps-020-beats-022-estimate

Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9....

 lucid-capital-markets-initiates-coverage-on-genelux-with-buy-rating-announces-price-target-of-10

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Pr...

 benchmark-maintains-speculative-buy-on-genelux-lowers-price-target-to-23

Benchmark analyst Bruce Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $25 ...

 hc-wainwright--co-reiterates-buy-on-genelux-maintains-30-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Genelux (NASDAQ:GNLX) with a Buy and maintains $30 price target.

 hc-wainwright--co-reiterates-buy-on-genelux-maintains-30-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Genelux (NASDAQ:GNLX) with a Buy and maintains $30 price target.

 genelux-concluded-meeting-with-fda-for-oli-vec-in-treatment-of-prroc

In response to a question seeking the FDA's guidance on their expectations regarding a confirmatory trial using the ongoing...

 genelux-and-newsoara-announce-preliminary-phase-1b2-data-of-olvi-vec-in-advanced-small-cell-lung-cancer

  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two...

 genelux-corp-tapped-matthew-pulisic-of-arrowhead-pharma-as-cfo-effective-january-30

Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has join...

 hc-wainwright--co-maintains-buy-on-genelux-lowers-price-target-to-30

HC Wainwright & Co. analyst Emily Bodnar maintains Genelux (NASDAQ:GNLX) with a Buy and lowers the price target from $32...

 genelux-q3-2024-gaap-eps-019-beats-020-estimate

Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 ...

 guggenheim-initiates-coverage-on-genelux-with-buy-rating-announces-price-target-of-8

Guggenheim analyst Kelsey Goodwin initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Price Target o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION